Drug intelligence / Profile preview

RES-102

Development stage: Preclinical
Lead developer: CervoMed
Modality: Small Molecules
Administration: Inhalation

Overview

RES-102 is a "soft" estrogen developed for the treatment of aging skin fragility/thinning and vulvo-vaginal atrophy. It was originally licensed from Yale University. RestorGenex Corporation transferred the exclusive rights to RES-102 to Or-Genix Therapeutics, Inc. in April 2015, allowing Or-Genix to continue its development.

Other names: soft estrogen

Targets

ER (Estrogen receptor)

Beyond the preview

Go deeper on RES-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RES-102.

Explore the full profile